Reopening During the Unprecedented: The Association of Biomolecular Resource Facilities Community Coronavirus Disease 2019 Pandemic Response. Part 2: E orts to E ectively Ramp Up Core Facility Activities

Shared research resources, also known as core facilities, serve a crucial role in supporting research, training, and other needs for their respective institutions. In response to the coronavirus disease (COVID-19) pandemic, all but the most critical laboratory research was halted in many institutions around the world. The Association of Biomolecular Resource Facilities conducted 2 surveys to understand and document institutional responses to the COVID-19 pandemic from core facility perspectives. The first survey was focused on initial pandemic response and efforts to sustainably ramp down core facility operations. The second survey, which is the subject of this study, focused on understanding the approaches taken to ramp up core facility operations after these ramp-down procedures. The survey results revealed that many cores remained active during the ramp-down, performing essential COVID-19 research, and had a more coordinated institutional response for ramping up research as a whole. The lessons gained from this survey will be indexed to serve as a resource for the core facility community to understand, plan, and mitigate risk and disruptions in the event of future disasters. Copyright © 2021, Association of Biomolecular Resource Facilities. All rights reserved.

Mobile On Demand COVID-19 Vaccine Production Units for Developing Countries

Two years into the COVID-19 pandemic and more than one year after the approval of the first vaccine, bottlenecks in production and supply chain infrastructure continue to delay vaccination campaigns in the Global South. Mobile on Demand (MOD) vaccine manufacture may help quickly ramp up production capacity while bypassing infrastructure bottlenecks. Such decentralized small-scale factories can help tip the scales in the battle against COVID-19 and future pandemics. In this work, we designed two MOD vaccine manufacturing units based on a protein antigen expressed in yeast and in vitro transcription of mRNA. Each unit consists of three shipping containers and can produce on the order of 10,000 vaccine doses daily for competitive prices and in close proximity of their end users. Abandoning economies of scale may lead to a moderate increase in production costs that may be outweighed by reduced closed-vial dose wastage and an earlier protection of vulnerable populations. © 2022 American Chemical Society.

Reopening During the Unprecedented: The Association of Biomolecular Resource Facilities Community Coronavirus Disease 2019 Pandemic Response. Part 2: Efforts to Effectively Ramp Up Core Facility Activities.

Shared research resources, also known as core facilities, serve a crucial role in supporting research, training, and other needs for their respective institutions. In response to the coronavirus disease (COVID-19) pandemic, all but the most critical laboratory research was halted in many institutions around the world. The Association of Biomolecular Resource Facilities conducted 2 surveys to understand and document institutional responses to the COVID-19 pandemic from core facility perspectives. The first survey was focused on initial pandemic response and efforts to sustainably ramp down core facility operations. The second survey, which is the subject of this study, focused on understanding the approaches taken to ramp up core facility operations after these ramp-down procedures. The survey results revealed that many cores remained active during the ramp-down, performing essential COVID-19 research, and had a more coordinated institutional response for ramping up research as a whole. The lessons gained from this survey will be indexed to serve as a resource for the core facility community to understand, plan, and mitigate risk and disruptions in the event of future disasters.

Planning a Mass Vaccination Campaign with Balanced Staff Engagement

The insurgence of the COVID pandemic calls for mass vaccination campaigns worldwide. Pharmaceutical companies struggle to ramp up their production to meet the demand for vaccines but cannot always guarantee a perfectly regular delivery schedule. On the other hand, governments must devise plans to have most of their population vaccinated in the shortest possible time and have the vaccine booster administered after a precise time interval. The combination of delivery uncertainties and those time requirements may make such planning difficult. In this paper, we propose several heuristic strategies to meet those requirements in the face of delivery uncertainties. The outcome of those strategies is a daily vaccination plan that suggests how many initial doses and boosters can be administered each day. We compare the results with the optimal plan obtained through linear programming, which however assumes that we know in advance the whole delivery schedule. As for performance metrics, we consider both the vaccination time (which has to be as low as possible) and the balance between vaccination capacities over time (which has to be as uniform as possible). The strategies achieving the best trade-off between those competing requirements turn out to be the q-days ahead strategies, which put aside doses to guarantee that we do not run out of stock on just the next q days. Increasing the look-ahead period, i.e. q, allows to achieve a lower number of out-of-stock days, though worsening the other performance indicators. © 2022, Springer Nature Switzerland AG.

Transmission dynamics of the COVID-19 epidemic in India and modeling optimal lockdown exit strategies.

India imposed one of the world's strictest population-wide lockdowns on March 25, 2020 for COVID-19. We estimated epidemiological parameters, evaluated the effect of control measures on the epidemic in India, and explored strategies to exit lockdown. We obtained patient-level data to estimate the delay from onset to confirmation and the asymptomatic proportion. We estimated the basic and time-varying reproduction number (R0 and Rt) after adjusting for imported cases and delay to confirmation using incidence data from March 4 to April 25, 2020. Using a SEIR-QDPA model, we simulated lockdown relaxation scenarios and increased testing to evaluate lockdown exit strategies. R0 for India was estimated to be 2·08, and the Rt decreased from 1·67 on March 30 to 1·16 on April 22. We observed that the delay from the date of lockdown relaxation to the start of the second wave increases as lockdown is extended farther after the first wave peak-this delay is longer if lockdown is relaxed gradually. Aggressive measures such as lockdowns may be inherently enough to suppress an outbreak; however, other measures need to be scaled up as lockdowns are relaxed. Lower levels of social distancing when coupled with a testing ramp-up could achieve similar outbreak control as an aggressive social distancing regime where testing was not increased.

Reconfiguring and ramping-up ventilator production in the face of COVID-19: Can robots help?

As the COVID-19 pandemic expands, the shortening of medical equipment is swelling. A key piece of equipment getting far-out attention has been ventilators. The difference between supply and demand is substantial to be handled with normal production techniques, especially under social distancing measures in place. The study explores the rationale of human-robot teams to ramp up production using advantages of both the ease of integration and maintaining social distancing. The paper presents a model for faster integration of collaborative robots and design guidelines for workstations. The scenario is evaluated for an open source ventilator through continuous human-robot simulation and amplification of results in a discrete event simulation.